Mast Cell Leukemia — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for mast cell leukemia. 2 active patents protecting 1 drugs from 1+ originators. First major cliff: 2028. Daily refresh.

1
Approved drugs
2
Active US patents
72/100
Avg vulnerability
$200M
Annual revenue covered

Originators in Mast Cell Leukemia

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Novartis 2 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating mast cell leukemia. Each bar = one year. Y-axis scaled to peak year (1 patents).

1
28
1
30

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Rydapt
MIDOSTAURIN
 Novartis 2 72 $200M 2028-10-09

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
7973031 Rydapt method of use 75 2028-10-09
8575146 Rydapt method of use 68 2030-12-02

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8575146 Rydapt method of use 68 2030-12-02
7973031 Rydapt method of use 75 2028-10-09

Related